Mucormycosis after allogeneic haematopoietic stem cell transplantation: A French Multicentre Cohort Study (2003-2008)

Service d'Hématologie- Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Université Paris-Diderot, Sorbonne Cité, Paris  Service des Maladies infectieuses et Tropicales, Centre d'Infectiologie Necker Pasteur, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris  Centre National de Référence Mycologie et Antifongiques, Institut Pasteur, Paris  Département de Bioinformatique Médicale, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Unité de Parasitologie-Mycologie, Laboratoire de Microbiologie, HEGP, Assistance Publique-Hôpitaux de Paris, Paris  Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Service d'Hématologie, Centre Hospitalier Universitaire Nancy, Nancy  Service de Parasitologie-Mycologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Département d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg  Service d'Hématologie, Centre Hospitalier Universitaire, Besançon,  Service d'Hématologie, Centre Hospitalier Universitaire Nantes, Nantes  Service d'Hématologie, Centre Hospitalier Universitaire Lyon, Lyon  Service d'Hématologie, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, et Université Paris-Est, Créteil  Service d'Hématologie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris  Service d'Hématologie, Centre Hospitalier Universitaire Saint-Etienne, Saint-Etienne  Service de Pneumologie, Hôpital Foch, Suresnes and  Service d'Hématologie, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
Clinical Microbiology and Infection (Impact Factor: 5.77). 05/2012; 18(10):E396-E400. DOI: 10.1111/j.1469-0691.2012.03908.x
Source: PubMed


Clin Microbiol Infect 2012; 18: E396-E400 ABSTRACT: We conducted a nationwide retrospective study to evaluate clinical characteristics and outcome of mucormycosis among allogeneic haematopoietic stem cell transplant recipients. Twenty-nine patients were diagnosed between 2003 and 2008. Mucormycosis occurred at a median of 225 days after allogeneic haematopoietic stem cell transplant, and as a breakthrough infection in 23 cases. Twenty-six patients were receiving steroids, mainly for graft-versus-host disease treatment, while ten had experienced a prior post-transplant invasive fungal infection. Twenty-six patients received an antifungal treatment; surgery was performed in 12. Overall survival was 34% at 3 months and 17% at 1 year.

Download full-text


Available from: Raoul Herbrecht, Jan 21, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucormycosis is an emerging cause of infectious morbidity and mortality in patients with hematologic malignancies. However, there are no recommendations to guide diagnosis and management. The European Conference on Infections in Leukemia assigned experts in hematology and infectious diseases to develop evidence-based recommendations for the diagnosis and treatment of mucormycosis. The guidelines were developed using the evidence criteria set forth by the American Infectious Diseases Society and the key recommendations are summarized here. In the absence of validated biomarkers, the diagnosis of mucormycosis relies on histology and/or detection of the organism by culture from involved sites with identification of the isolate at the species level (no grading). Antifungal chemotherapy, control of the underlying predisposing condition, and surgery are the cornerstones of management (level A II). Options for first-line chemotherapy of mucormycosis include liposomal amphotericin B and amphotericin B lipid complex (level B II). Posaconazole and combination therapy of liposomal amphotericin B or amphotericin B lipid complex with caspofungin are the options for second line-treatment (level B II). Surgery is recommended for rhinocerebral and skin and soft tissue disease (level A II). Reversal of underlying risk factors (diabetes control, reversal of neutropenia, discontinuation/taper of glucocorticosteroids, reduction of immunosuppressants, discontinuation of deferroxamine) is important in the treatment of mucormycosis (level A II). The duration of antifungal chemotherapy is not defined but guided by the resolution of all associated symptoms and findings (no grading). Maintenance therapy/secondary prophylaxis must be considered in persistently immunocompromised patients (no grading).
    Full-text · Article · Sep 2012 · Haematologica
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucormycosis is an infection caused by filamentous fungi of the Mucorales order. The predisposing factors are mostly diabetic ketoacidosis and severe immunosuppressive conditions such as prolonged neutropenia, steroid or T-cell suppressor therapy, solid organ transplantation or allogeneic hematopoietic stem cell transplantation. Mucormycosis can also occur in immunocompetent patients, especially after trauma, burns or direct inoculation of the fungi (e.g. intravenous drug abuse). The most frequently targeted primary sites of infection are sinuses with a rapid spread to the adjacent tissues including the brain, the lower respiratory tract, the digestive tract and the skin. Mucorales are able to invade the vessels causing hematogenous dissemination, vascular thrombosis and, ultimately, necrosis of the lesions. Clinical and radiological aspects are similar to those observed in other invasive filamentous fungi infections such as invasive aspergillosis, fusariosis or scedosporiosis. CT-scan or MRI are mandatory to assess the extension of the lesions. The diagnosis remains difficult and is often delayed resulting in a poor outcome.
    Preview · Article · Mar 2013 · Medecine sciences: M/S
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections are an important cause of morbidity and mortality in hematopoietic stem cell transplant and solid organ transplant recipients. Evolving transplant modalities and techniques, complex and extensive immunosuppressant strategies, and the increased use of broad spectrum antifungal prophylaxis has greatly impacted the epidemiology and temporal pattern of invasive fungal infections in the transplant population. The goal of this article is to provide an up-to-date review of the most commonly encountered invasive fungal infections seen in transplant recipients, including epidemiology, risk factors, clinical features, diagnostic dilemmas, management and their overall influence on outcomes.
    Full-text · Article · Jun 2013 · Therapeutic Advances in Infectious Disease
Show more